http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2512448-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2fd608e2502870384abc13bfbb3377e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78f10c5588215c370b2d84187fff2dd8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4891 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 2010-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8db04d481d441ab74f54603c72b08549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b6b72162e05db9798f6d440b4c410e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62de10e90de54c68acd854599ea674f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bfcdf7a4f0567d5646de31d82e0a473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_325491160473a6022581e06ffe3f9a7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8675ccec8f47904b47e586629293e7a8 |
| publicationDate | 2012-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2512448-A2 |
| titleOfInvention | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
| abstract | The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1 % by weight of the total weight of the formulation, b) a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70 % by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30 % by weight of the total weight of the formulation, d) at least one hydrophilic surfactant (D) with HLB above 7 in an amount of up to 20% by weight of the total weight of the formulation, advantageously up to 15% by weight of the total weight of the formulation, e) optionally, at least one hydrophilic solvent (E) in an amount of up to 15% by weight of the total weight of the formulation, advantageously up to 10% by weight of the total weight of the formulation, f) between 0 and 30% by weight of the total weight of the formulation of a chemical and/or physical stabilization agent (F), advantageously between 0 and 20 % by weight of the total weight of the formulation, wherein when the formulation is in a form of a reverse emulsion or microemulsion and contains at least one hydrophilic solvent (E), the physical stabilization agent is present and is silicon dioxide. |
| priorityDate | 2009-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.